Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
3.030
+0.120 (4.12%)
At close: Aug 13, 2025, 4:00 PM
3.030
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:33 AM EDT
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Taysha Gene Therapies stock ranges from a low of $6.00 to a high of $14. The average analyst price target of $8.71 forecasts a 187.46% increase in the stock price over the next year.
Price Target: $8.71 (+187.46%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Taysha Gene Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $7.5 → $8 | Buy | Maintains | $7.5 → $8 | +164.03% | Aug 13, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $14 | Strong Buy | Maintains | $11 → $14 | +362.05% | Aug 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +230.03% | Aug 12, 2025 |
| B of A Securities | B of A Securities | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +164.03% | Jul 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +164.03% | Jul 1, 2025 |
Financial Forecast
Revenue This Year
7.29M
from 8.33M
Decreased by -12.55%
Revenue Next Year
4.62M
from 7.29M
Decreased by -36.65%
EPS This Year
-0.34
from -0.36
EPS Next Year
-0.39
from -0.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | 15.8M | 53.2M | ||
| Avg | 7.3M | 4.6M | 15.0M | ||
| Low | 2.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 89.0% | 116.1% | 1,053.3% | ||
| Avg | -12.6% | -36.7% | 225.3% | ||
| Low | -73.0% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.30 | -0.33 | -0.28 | ||
| Avg | -0.34 | -0.39 | -0.36 | ||
| Low | -0.37 | -0.54 | -0.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.